Myelodysplastic Syndromes (MDS)

Treatment of high-risk myelodysplastic syndromes

Myelodysplastic syndrome (MDS) is considered to be a heterogeneous myeloid malignancy with a common origin in the hematopoietic stem cell compartment and is generally divided into lower- and higher-risk forms. While the treatment goals for lower-risk MDS are to decrease transfusion requirements and transformation into acute leukemia, the major aims for higher-risk MDS are to prolong survival and ultimately cure the patient.

How is transfusion dependence evolving in anemia treatment in MDS?

Original Publication Date
Article Source
External Web Content
A roundtable discussion on anemia management in myelodysplastic syndromes. Featuring moderator Guillermo Garcia-Manero, MD, of the University of Texas MD Anderson Cancer Center; Amy DeZern, MD, MHS, Johns Hopkins Medicine; Tiffany Tanaka, MD, of the University of California San…

Jane Biehl: Moving Slower and Slower After Myelodysplastic Syndrome

Original Publication Date
Article Source
External Web Content
I have honestly been frustrated lately. I am slowing down increasingly, and it has even become noticeable to others. I wrote an article in November about how nice it was to slow down and smell the roses. But now it seems like too much. In my previous life (before cancer), I moved…

What are some of the new therapies discussed at ASH 2024?

Original Publication Date
Article Source
External Web Content
A roundtable discussion on anemia management in myelodysplastic syndromes featuring moderator Guillermo Garcia-Manero, MD, of the University of Texas MD Anderson Cancer Center; Amy DeZern, MD, MHS, Johns Hopkins Medicine; Tiffany Tanaka, MD, of the University of California San…

Diagnosis of TP53-mutated myeloid disease by the ICC and WHO fifth edition classifications

Original Publication Date
Article Source
External Web Content
Key Points The ICC and WHO5 differently classify 64% of TP53-mutated disease due to distinct criteria for multihit TP53 mutations and TP53-mutated AML. MDS with a single TP53 mutation and CK is similar to MDS with biallelic TP53 abnormalities, whereas TP53-mutated AML is distinct…

ACROBAT interim results support AlloHeme for relapse prediction in AML, MDS

Original Publication Date
Article Source
External Web Content
Interim results of the ACROBAT study suggest that increasing microchimerism and loss of complete chimerism may indicate relapse risk in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). The findings were presented in an oral abstract1 at the 2025…

Genome sequencing in the management of myelodysplastic syndromes and related disorders

Original Publication Date
Article Source
External Web Content
Abstract Myeloid neoplasms originate from the clonal proliferation of hematopoietic stem cells, which is driven by the acquisition of somatic genetic mutations. Within these disorders, myelodysplastic syndromes (MDS) are specifically characterized by morphological abnormalities…

Oppose 57% Cut to Congressionally Directed Medical Research Programs

Original Publication Date
Article Source
Community Impact
Oppose 57% Cut to Congressionally Directed Medical Research Programs Take Action Before House Vote Oppose 57% Cut to Congressionally Directed Medical Research Programs Tell your Members of Congress to Vote NO on The Full-Year Continuing Appropriations and Extensions Act, 2025 As…
Subscribe to Myelodysplastic Syndromes (MDS)

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.